Celcuity Inc. — Q2 2022 Form 10-Q Summary
Reporting period: Three and six months ended June 30, 2022. Celcuity is a clinical-stage biotechnology company developing gedatolisib and its CELsignia companion diagnostic platform. It has not generated revenue and reports no product margins.
Financial performance and position
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development | $8.37 million | $13.07 million | $15.06 million | $15.31 million |
| General and administrative | $1.23 million | $0.57 million | $2.04 million | $1.13 million |
| Net loss | $9.96 million | $14.03 million | $17.89 million | $16.82 million |
| Basic and diluted loss per share | $0.67 | $1.11 | $1.20 | $1.42 |
| Operating cash used | Not separately reported | Not separately reported | $17.22 million | $10.14 million |
- At June 30, cash and cash equivalents were $66.91 million, down from $84.29 million at December 31, 2021. Current assets were $71.96 million and current liabilities were $4.15 million.
- Accumulated deficit was $73.82 million. Total liabilities were $19.16 million, including a note payable with a $15.01 million carrying value. The loan is secured by substantially all company assets; its effective interest rate was 12.85%.
- Net cash used in investing activities was $0.03 million and financing activities used $0.12 million in the first half. Cash declined by $17.38 million overall.
Material changes versus comparable periods
- Q2 operating expenses fell 30% and net loss narrowed 29% year over year. R&D declined 36%, primarily because Q2 2021 included a $10 million Pfizer license upfront fee; higher clinical-trial and VIKTORIA-1 preparation costs partly offset that comparison.
- For the first half, operating expenses rose 4% and net loss increased 6%. R&D was nearly flat as increased trial, personnel, and VIKTORIA-1 costs largely offset the prior-year license fee. G&A increased 81%, including higher employee-related costs and stock-based compensation.
- First-half operating cash use increased from $10.14 million to $17.22 million, notably reflecting a $3.88 million increase in prepaid assets and the absence of the prior-year $5 million noncash stock issuance for the Pfizer license in the cash-flow reconciliation.
Outlook, developments, and risks
- Management expected to initiate the VIKTORIA-1 Phase 3 study in 2022; in August it said the study remained on track to dose its first patient in the next few months. The first U.S. patient dose by December 31, 2022 was a condition to closing the May private placement.
- Gedatolisib received FDA Breakthrough Therapy Designation on July 18, 2022. This may support expedited development and review but is not FDA approval. The company cited Phase 1b data; those results are not confirmatory Phase 3 evidence.
- Management stated that cash on hand was expected to fund operations and obligations for at least the next 12 months. The company also expects R&D and G&A spending to increase and may need additional capital; financing may be unavailable or dilutive.
- On May 15, the company agreed to a proposed $100 million private placement at $5.75 per share on an as-converted basis, with warrants and potential preferred-stock conversion. It remained subject to conditions, including the first U.S. VIKTORIA-1 patient dose. The filing does not report that the placement had closed by June 30.
- On August 9, after quarter-end, Innovatus amended the loan facility to allow up to $75 million in total term loans, subject to closing and other conditions, clinical milestones, and financial covenants. The additional borrowing is not assured and would add secured debt; amended terms also include lender conversion rights and fees.
- Pfizer’s license may require up to $335 million in development and commercial milestone payments and tiered royalties in the low-to-mid teens on sales. As of June 30, one material non-cancelable clinical research commitment was approximately $2.6 million.
- COVID-19-related enrollment delays pushed expected interim results from CELsignia Phase 2 trials FACT-1 and FACT-2 to mid-2023, with final results expected about nine months later. Further delays remain possible.
- Other key risks include clinical and regulatory uncertainty, dependence on gedatolisib and CELsignia, competition, partner and market adoption, reimbursement, financing needs, and potential dilution. No material legal proceedings were reported. Management concluded disclosure controls were effective.
Important facts for investors to verify
- Whether and when the $100 million private placement closed, including actual proceeds, warrant terms, and resulting dilution.
- VIKTORIA-1 enrollment and first-dose timing, protocol and study-arm details, and whether the study meets its milestones.
- Actual cash burn and runway as trial spending rises, and the availability and conditions of additional Innovatus tranches.
- Clinical-trial timelines and results, including COVID-related delays and the distinction between preliminary Phase 1b findings and Phase 3 outcomes.
- Future obligations under the Pfizer license, including milestone triggers and royalties if gedatolisib is commercialized.